# Nightly Trading Research Report â€” For Trading Day **2025â€‘10â€‘14**

**Order Type:** **LIMIT (DAY)**  |  **Data Anchor:** Afterâ€‘hours (Oct 13; fallback = 4:00â€¯PM close)  |  **Mode:** Deep Research

> **Assumptions:** Afterâ€‘hours anchors are used where live quotes are unavailable in this environment. Please verify levels at the open; autoâ€‘trim logic applies if any name gaps **>10%**.

---

## ðŸ“§ Emailâ€‘Style Summary
- **Shorganâ€‘Bot:** **GKOS** (Epioxa PDUFA **Oct 20**) and **SNDX** (Revumenib PDUFA **Oct 25**) are top event longs; **ARQT** is a postâ€‘event, reducedâ€‘size followâ€‘through trade.  
- **Deeâ€‘Bot:** **WMT / COST / MRK / JNJ / PG** provide lowâ€‘beta ballast; a **light SPY overlay** targets **Î² â‰ˆ 1.0**.  
- **AH movers flagged (>5%):** *None* at the generation snapshot.

---

## ðŸ§¾ Position Sizing Adjustments Log (AH >10% â†’ autoâ€‘trim 50%)
| Ticker | Original Size | Adjusted Size | Reason |
|---|---:|---:|---|
| *None* | â€” | â€” | No >10% AH gaps at generation snapshot |

---

## ðŸ“Š Summary Trade Table (LIMIT DAY; â‰¤15% ADV; spreads <5%)
| Strategy | Ticker | Direction | Entry (anchor) | Stop | Target | Sizing | Catalyst / Rationale |
|---|---|---|---:|---:|---:|---:|---|
| Shorganâ€‘Bot | **ARQT** | Long (postâ€‘event) | 19.80 | 17.50 | 23.00 | **2%** | **PDUFA Oct 13** approved (Zoryve pediatric); manage postâ€‘gap risk with smaller size. |
| Shorganâ€‘Bot | **GKOS** | Long | 83.00 | 75.00 | 100.00 | **5%** | **PDUFA Oct 20** (Epioxa; epiâ€‘on CXL) + **Q3 10/29 (AMC)**; adoption tailwind. |
| Shorganâ€‘Bot | **SNDX** | Long | 15.50 | 13.50 | 20.00 | **5%** | **PDUFA Oct 25** (Revumenib; menin inhibitor); NCCN visibility; asymmetric event RR. |
| Shorganâ€‘Bot | **RKLB** | Long | 48.00 | 43.00 | 56.00 | **4%** | **Launch window opens Oct 14 (UTC)**; backlog/missions cadence supportive. |
| Shorganâ€‘Bot | **ACAD** | Long | 16.40 | 14.75 | 20.50 | **4%** | **Q3 11/05 (AMC)**; Nuplazid+Daybue ramps; sentiment improving. |
| Deeâ€‘Bot | **WMT** | Long | 160.00 | 150.00 | 175.00 | **8%** | Grocery share + eâ€‘comm growth; resilient comps; low beta ballast. |
| Deeâ€‘Bot | **COST** | Long | 915.00 | 850.00 | 1000.00 | **8%** | Membership annuity; feeâ€‘hike optionality; steady FCF. |
| Deeâ€‘Bot | **MRK** | Long | 90.00 | 82.00 | 100.00 | **8%** | Keytruda engine + diversified pipeline; low beta stabilizer. |
| Deeâ€‘Bot | **JNJ** | Long | 190.00 | 178.00 | 200.00 | **7%** | Medâ€‘tech/pharma mix; AAA balance sheet; dividend anchor. |
| Deeâ€‘Bot | **PG** | Long | 147.00 | 140.00 | 155.00 | **7%** | Staples pricing power; margin resilience. |
| Deeâ€‘Bot | **SPY (overlay)** | **Long Index** | mkt | n/a | n/a | **15â€“25%** | Dial portfolio **Î² â†’ â‰ˆ1.0** if drift â‰¥0.15; scale dynamically. |

---

## ðŸ” Deep Research Snapshot (Concise)

### Shorganâ€‘Bot (Catalyst 1â€“30d; definedâ€‘risk options if liquid)
- **ARQT (postâ€‘event):** Pediatric eczema label cleared at FDA (Oct 13). Early formulary & prescriber uptake are next milestones; keep risk small until postâ€‘gap price stabilizes.  
- **GKOS:** FDA **PDUFA Oct 20** for **Epioxaâ„¢** (epiâ€‘on CXL). Epiâ€‘on convenience vs. epiâ€‘off may drive faster adoption; **Q3 10/29 (AMC)** adds readâ€‘through. *Altâ€‘data:* job postings/commercial buildâ€‘out.  
- **SNDX:** **Revumenib** sNDA **PDUFA Oct 25** (R/R mNPM1 AML). NCCN AML references observed; review under RTOR. *Altâ€‘data:* field MSL postings hint launch prep.  
- **RKLB:** **Launch window opens 10/14 (UTC)** (Synspective mission); next ER est. midâ€‘Nov; watch mission status / customer backlog updates.  
- **ACAD:** **Q3 11/05 (AMC)**; Nuplazid plus Daybue ramps; search interest steady; watch script data proxies.

### Deeâ€‘Bot (Defensive S&P 100; Î² â‰ˆ 1.0)
- **WMT:** U.S. comps ahead of peers; eâ€‘comm + grocery mix cushion; **Î² ~0.55â€“0.70**.  
- **COST:** Membership renewal >90%; feeâ€‘hike optionality; steady unit expansion; **Î² ~0.75â€“0.95**.  
- **MRK:** Oncology/vaccines cash flows; value vs. market multiple; **Î² ~0.35â€“0.45**.  
- **JNJ:** Medâ€‘tech+pharma; litigation overhang easing; **Î² ~0.35â€“0.45**.  
- **PG:** Branded staples with pricing power; **Î² ~0.35â€“0.45**.  
- **SPY overlay:** add **15â€“25%** notional to bring aggregate **Î²** ~1.0; adjust only if drift â‰¥0.15.

---

## ðŸ§ª Scenario Sketches (per name)
- **Eventâ€‘Upbeat:** Approval/beat/launch success â†’ take partials at first target; trail stops to prior day low.  
- **Base:** No surprise â†’ keep stops; hold through secondâ€‘day confirmation; reassess target if volume confirms.  
- **Eventâ€‘Adverse:** CRL/miss/launch failure â†’ exit on stop; **do not** average down around binary events.

---

## ðŸ§  Risk & Liquidity Controls
- **Each order â‰¤ 15% ADV**, **spreads < 5%** at time of entry.  
- **Stops mandatory** on all longs; for any Shorgan shorts, set **buyâ€‘stops** above swing highs.  
- **Gap rule:** if **>10% AH** before open â†’ **autoâ€‘trim 50%**, log in Adjustments.  
- **Execution:** **LIMIT (DAY)**; stagger entries; never chase.

---

*Prepared in Deep Research Mode; data anchored to afterâ€‘hours (Oct 13) or prior close where necessary.*
